BRCA2 and ovarian cancer: This is supported by the fact that studies of prevalence of BRCA1 and BRCA2 mutations in French-Canadian patients with breast and ovarian cancer unselected for family history indicate similar prevalences of mutations as in the UK population and much lower than the prevalence of mutations among Ashkenazi Jewish women [44,45,48-50].